{"name":"POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company","slug":"point-biopharma-a-wholly-owned-subsidiary-of-eli-lilly-and-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"[Lu-177]-PNT2002","genericName":"[Lu-177]-PNT2002","slug":"lu-177-pnt2002","indication":"Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","status":"phase_3"}]}],"pipeline":[{"name":"[Lu-177]-PNT2002","genericName":"[Lu-177]-PNT2002","slug":"lu-177-pnt2002","phase":"phase_3","mechanism":"[Lu-177]-PNT2002 is a lutetium-177 labeled radioligand that targets somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells, delivering targeted radiation therapy.","indications":["Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","SSTR2-positive neuroendocrine tumors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOQkxmbk12TjRSRXhEVnFZTGotcy1sUlZsYXdPSTNBeV9BTk40QnJraDBzeHppNGpuR0JLVmk3TV82a0drdXhTdUpGOTgzMk5DbVdlclZYMTQzSzlfelE1eTdwYXpGVXBNMzV6eW05ZjBPLTFTMHF5TUNscEVlTkhqWQ?oc=5","date":"2025-12-19","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQLUhLT0dzT1JmQUZELWxaWjI1Q0k0ZFJCOEt0SHJhT0ZGMFJJNTB3Z3g5VGl5LXBNUlFQYklfSlFwU2VuTGN6TVhNZEY5UnRzcmxaRmZFYVFtTlNqc2liM01PVGc3dmFZQU5GUHMzNzBJQ3VyNk1sM2ZLRTE0YTFvR0lkeUFNSUduQU5ic3huOGlnMFJEcjkxNmlLQ0lNZUc0X1ZRdWpWWnVZd2VORUE?oc=5","date":"2025-10-02","type":"pipeline","source":"MedCity News","summary":"Scaling Radioligand Therapy: 3 Essential Strategies From Inside The Ecosystem - MedCity News","headline":"Scaling Radioligand Therapy: 3 Essential Strategies From Inside The Ecosystem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZ2h0SVI0S0dCUWVxWmNLNmZJS3RiOFVGNjJadEJYSWV5NTY3OUd5WGRKVV9vM2g3bEluT1lFQVlrVVhuYWpxVXd3b3BZZ1pxa051cVZrSEpTeFRMRWxxNzVueUlNbnEwbUdIRWVSN0tYZTNUQTRobkhmWng0WmY1cldpYmxoNnZIRmw1bnNkdXhWSjdIc0lyc1VjbmFUV21lcFdybEhONWU?oc=5","date":"2025-01-10","type":"pipeline","source":"Fierce Pharma","summary":"2025 forecast: As companies rush to radiopharmaceuticals for oncology, what's next? - Fierce Pharma","headline":"2025 forecast: As companies rush to radiopharmaceuticals for oncology, what's next?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdnc2MDRiTHk0NnU0NzBpdWZLalRYQWJoU1BaLWYtay1BVmpOQkxLTFQ0TERIaDVsa2FWTHctRnpuS1RDc1lYeFhkVXBUQTlDWHMzY2FTT3NmSEVkejNoQTlyY2R5aG1zdUIwbkZPUDdaV3AyV0RGekRuTXJCalhxSko1aWMzSE00Z184UEdLd2tZTlNnaFhHd2MyRjBpdEdjWXhETDZtSHA?oc=5","date":"2023-12-27","type":"pipeline","source":"Eli Lilly","summary":"Lilly Completes Acquisition of POINT Biopharma - Eli Lilly","headline":"Lilly Completes Acquisition of POINT Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPSU5HQ0QxdjlJSmFlWWpIRXRzanNsQ3lldE9pUFhzd1I3UzE3YjIyNjgwMHlzblltclhIZFl0Wmt5WnpYVVhJRGlIOUhheU1oV2I5ekJhRGlQS25wVzh6QXljMlBpMWhCQ2RCZGYtSTdUR0NvQURjeExjcU9JcUZ3ZDQ4azdHUExFSXhCZFFwVVRkYkhSZml6UW1jSWVUeHNTaXNqVnpWdkdBbzFCTGZzSlUyYlI?oc=5","date":"2023-11-12","type":"deal","source":"Powder & Bulk Solids","summary":"Lilly to Acquire POINT Biopharma for $1.4 Billion - Powder & Bulk Solids","headline":"Lilly to Acquire POINT Biopharma for $1.4 Billion - Powder & Bulk Solids","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPR1RQa001Zk91TGdCd1BseWNaVzhsLW9ON1Y2N2hibWpMbUk4ZlhzSzNVdFZaNk9oN0gtdlRJbWxleVpMUDhnQTBXS0VSc1hRdzBqVHd3S3FDNFgtSUdVNVgzQzc2YnN1YmQ2MVowMENwcS14TGxYbWthQnJiU3hucQ?oc=5","date":"2023-10-05","type":"pipeline","source":"C&EN","summary":"Lilly bets on radiopharmaceuticals - C&EN","headline":"Lilly bets on radiopharmaceuticals - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQR2tCaDNzQk50dDZjelZQbW9qeWMwY0pDOGtLeDFjMS1jX0tWaUFwZFhqaU9YOEV6SE1fNXp0Z21VS2dMUmlnWTFnbl9VOTdZYnFKOUstMWczc2ktekN4RzVKLUhzMTZheDU1ZllBX2pYTUlkV3N3ZEZQTjNaMUhSNnoxYzFxYU92TjdsUlFXYlVHdlYxamVfYTVpNFFmancyZTlOaFhPbWRxWVk?oc=5","date":"2023-10-04","type":"pipeline","source":"European Pharmaceutical Review","summary":"Lilly agrees $1.4 billion radiopharma acquisition - European Pharmaceutical Review","headline":"Lilly agrees $1.4 billion radiopharma acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9qMXdzWWJvcHZ6WFlJMGhfeTBuSFdCRFVNU3QtT2lXUUxEeUttLVM0bzRSV2ktbjNhZWMxSUxrSHlpY1VsTng4Zm4zMnBJZmlYM3ZFSlRPcHdES2dtV0RDSUdaUkRmTzBYNS1kUTlpd0Ywdw?oc=5","date":"2023-10-04","type":"pipeline","source":"pharmaphorum","summary":"Lilly takes POINT in radiopharma push - pharmaphorum","headline":"Lilly takes POINT in radiopharma push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOa2FyTFRiaFVtRXZKdmJOWDNhVU9IcDI1b0d4bkotcFBpQ1otSjZWamdMVkxzVGdyY05mU2ZZVWg4cG1DR184clFVNS02eTBIbHFXREdVVzZUMFJrTmtCOXVNLTY0M3ZTR28tUnlkWGJ1QWE1NWhzaU4wS3lrOWZzMk43a0ktWDlhOHlIa1hKRk9JdTVfTjZLTXpPZUNGSzRWd3J2Nk1fX3lfV2hw?oc=5","date":"2023-10-03","type":"pipeline","source":"statnews.com","summary":"Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion - statnews.com","headline":"Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNeWlHVWlvTzZmRVh3cnExX0lIX1BkTTZLSlhlNjNXRllnZm1iSzlScFMtbC0yd0lUWm1WQzFQTWstYUt3Zm9Qam55c0xXTllJbXZDZnlTTXZYMlp6cjJDTlMwM0tZS0hsT2ZYVFYyVUVlOXYydUxCUE11ZVJCLWZkdEhEVkhOVUdNUVVDdnh0UEcxdXR3LWdkYllMcEgtclIwVlBTSmhxZnQxWlZL?oc=5","date":"2023-10-03","type":"deal","source":"BioPharma Dive","summary":"Lilly to enter radiopharmaceutical drug field with $1.4B Point buyout - BioPharma Dive","headline":"Lilly to enter radiopharmaceutical drug field with $1.4B Point buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPQjluUXpvYjNVR2JLWWlWaklSelZKdzZ1Ukoyc1RLQWM0bjRqLWpWYVJKcnRkQ3p2SEFnQXZSS1prbzJJS050UHNabjRmZmRjbG5kcjUwNDhFVFZvVlg3UFMtSXVTS1NrWGpUSENNRVBLU1lqMnBqUFBtTVZaWFZIMjQ5M1ZuaW9sV3JaU0EtX0sxMndIVzJLd2tEYnpYSkNHR2tlZVV2NVVjZw?oc=5","date":"2023-10-03","type":"deal","source":"BioWorld News","summary":"Lilly enters radiopharma space with $1.4B buyout of Point Biopharma - BioWorld News","headline":"Lilly enters radiopharma space with $1.4B buyout of Point Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQTE84NENZM1JUZXVnbDBOdnJHWnVlT0NZRHlBMUx6QWVtankxajRWcnhmVDlBOF94MTJtbDNuZXNwb0I3aTYyRU40RVNxUk5EcDBJMEp3U09zNDREaGhSRnN3TnlXZUhYY2NaOHFLeVVtVFBrYUtfRks0RHdYbUlSTFZSQWhJOEVYMm1LUFBhVWtZZWxDS1FuRnpfMXJ5SndqdjVoM21uWER3NlFrSnJRY1NXNHRsaWp1S1Y2cGJDSVBBdGM?oc=5","date":"2023-10-03","type":"deal","source":"Eli Lilly","summary":"Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies - Eli Lilly","headline":"Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}